These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 1523609)

  • 21. Antithrombotic activity of avian crown dermatan sulfate.
    Kyogashima M; Onaya J; Miyauchi S; Arai M; Shibata Y; Suda A; Sakai T; Takada Y; Takada A
    Thromb Res; 1999 Dec; 96(6):459-65. PubMed ID: 10632469
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Low molecular weight heparin is responsible for the anti-Xa activity of Desmin 370.
    Brieger D; Dawes J
    Thromb Haemost; 1996 Feb; 75(2):286-91. PubMed ID: 8815578
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacodynamic study of low molecular weight dermatan sulphate (Desmin) after a single subcutaneous administration in patients with renal insufficiency.
    Saivin S; Boneu B; Ducret F; Pourrat J; Palazzini E; Zamboni W; Duchêne P; Houin G
    Arzneimittelforschung; 2000 Sep; 50(9):821-6. PubMed ID: 11050699
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Structural features of dermatan sulfates and their relationship to anticoagulant and antithrombotic activities.
    Linhardt RJ; al-Hakim A; Liu JA; Hoppensteadt D; Mascellani G; Bianchini P; Fareed J
    Biochem Pharmacol; 1991 Sep; 42(8):1609-19. PubMed ID: 1930287
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Low molecular weight dermatan sulfate as an antithrombotic agent. Structure-activity relationship studies.
    Linhardt RJ; Desai UR; Liu J; Pervin A; Hoppensteadt D; Fareed J
    Biochem Pharmacol; 1994 Mar; 47(7):1241-52. PubMed ID: 8161353
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A survey of the clinical experience with dermatan sulfate.
    Gianese F; Lucchelli PE
    Semin Thromb Hemost; 1991; 17 Suppl 2():199-204. PubMed ID: 1948090
    [No Abstract]   [Full Text] [Related]  

  • 27. Low-molecular-weight heparin and dermatan sulfate end group-labeled with tyramine and fluorescein. Biochemical and biological characterization of the fluorescent-labeled heparin derivative.
    Harenberg J; Casu B; Guerrini M; Malsch R; Naggi A; Piazolo L; Torri G
    Semin Thromb Hemost; 2002 Aug; 28(4):343-54. PubMed ID: 12244481
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics of native and low molecular weight dermatans: preliminary studies in rats and primates.
    Bergonzini GL; Bianchini P; Hoppensteadt D; Parma B; Osima B; Walenga JM; Fareed J
    Semin Thromb Hemost; 1991; 17 Suppl 2():235-9. PubMed ID: 1948095
    [No Abstract]   [Full Text] [Related]  

  • 29. Molecular and functional heterogeneity in dermatan sulfate preparations.
    Fareed J; Hoppensteadt D; Walenga JM; Ahsan A; Coyne E; Breddin HK
    Semin Thromb Hemost; 1991; 17 Suppl 2():174-80. PubMed ID: 1948088
    [No Abstract]   [Full Text] [Related]  

  • 30. Effect of nonspecific binding to plasma proteins on the antithrombin activities of unfractionated heparin, low-molecular-weight heparin, and dermatan sulfate.
    Cosmi B; Fredenburgh JC; Rischke J; Hirsh J; Young E; Weitz JI
    Circulation; 1997 Jan; 95(1):118-24. PubMed ID: 8994426
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Dermatan sulfate and the prevention of experimental venous thrombosis].
    Desnoyers P; Bara L; Samama M
    Pathol Biol (Paris); 1989 Jun; 37(6):759-67. PubMed ID: 2674877
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anticoagulant dermatan sulfate proteoglycan (decorin) in the term human placenta.
    Delorme MA; Xu L; Berry L; Mitchell L; Andrew M
    Thromb Res; 1998 May; 90(4):147-53. PubMed ID: 9692613
    [TBL] [Abstract][Full Text] [Related]  

  • 33. M118--a rationally engineered low-molecular-weight heparin designed specifically for the treatment of acute coronary syndromes.
    Kishimoto TK; Qi YW; Long A; Capila I; Sasisekharan R; Guerrero L; Fier I; Roach J; Venkataraman G
    Thromb Haemost; 2009 Nov; 102(5):900-6. PubMed ID: 19888526
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The additive effect of low molecular weight heparins on thrombin inhibition by dermatan sulfate.
    Cosmi B; Agnelli G; Young E; Hirsh J; Weitz J
    Thromb Haemost; 1993 Sep; 70(3):443-7. PubMed ID: 8259546
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of increased sulfation of dermatan sulfate on its in vitro and in vivo pharmacological properties.
    Dol F; Caranobe C; Dupouy D; Petitou M; Lormeau JC; Choay J; Sié P; Boneu B
    Thromb Res; 1988 Oct; 52(2):153-64. PubMed ID: 3194890
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The importance of thrombin inhibition for the expression of the anticoagulant activities of heparin, dermatan sulphate, low molecular weight heparin and pentosan polysulphate.
    Ofosu FA; Blajchman MA; Modi GJ; Smith LM; Buchanan MR; Hirsh J
    Br J Haematol; 1985 Aug; 60(4):695-704. PubMed ID: 2411283
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The pharmacokinetics of LMW dermatan sulphate: long-term persistence of intact material.
    Dawes J
    Thromb Haemost; 1993 Apr; 69(4):339-43. PubMed ID: 8497846
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dermatan sulfate as a potential therapeutic agent.
    Linhardt RJ; Hileman RE
    Gen Pharmacol; 1995 May; 26(3):443-51. PubMed ID: 7789716
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antithrombotic activity of Desmin 370. Comparison with a high molecular weight dermatan sulfate.
    Barbanti M; Calanni F; Babbini M; Bergonzini G; Parma B; Marchi E; Wassermann A
    Thromb Res; 1993 Sep; 71(5):417-22. PubMed ID: 8236168
    [No Abstract]   [Full Text] [Related]  

  • 40. Synthesis and biological effects of N-alkylamine-labeled low-molecular-mass dermatan sulfate.
    Malsch R; Guerrini M; Berti C; Naggi A; Torri G; Casu B; Harenberg J
    Semin Thromb Hemost; 1997; 23(2):99-107. PubMed ID: 9200333
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.